Standout Papers

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated ... 2004 2026 2011 2018 3.4k
  1. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib (2004)
    William Pao, Vincent A. Miller et al. Proceedings of the National Academy of Sciences
  2. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2005)
    William Pao, Vincent A. Miller et al. PLoS Medicine
  3. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers (2013)
    Helena A. Yu, Maria E. Arcila et al. Clinical Cancer Research
  4. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (2005)
    William Pao, Gregory J. Riely et al. PLoS Medicine
  5. New driver mutations in non-small-cell lung cancer (2011)
    William Pao, Nicolas Girard The Lancet Oncology
  6. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010)
    William Pao, Juliann Chmielecki Nature reviews. Cancer
  7. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer (2009)
    Christopher G. Azzoli, Sherman Baker et al. Journal of Clinical Oncology
  8. Acquired resistance to TKIs in solid tumours: learning from lung cancer (2014)
    D. Ross Camidge, William Pao et al. Nature Reviews Clinical Oncology
  9. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors (2006)
    Marissa N. Balak, Yixuan Gong et al. Clinical Cancer Research
  10. Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer (2009)
    David M. Jackman, William Pao et al. Journal of Clinical Oncology
  11. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer (2004)
    Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology
  12. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib (2006)
    Gregory J. Riely, William Pao et al. Clinical Cancer Research
  13. Anchored multiplex PCR for targeted next-generation sequencing (2014)
    Zongli Zheng, Matthew Liebers et al. Nature Medicine
  14. HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation (2012)
    Ken Takezawa, Valentina Pirazzoli et al. Cancer Discovery
  15. Syk tyrosine kinase required for mouse viability and B-cell development (1995)
    Alec M. Cheng, Bruce R. Rowley et al. Nature
  16. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas (2007)
    Sizhi Paul Gao, Kevin G. Mark et al. Journal of Clinical Investigation
  17. Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions (2005)
    William Pao, Vincent A. Miller Journal of Clinical Oncology
  18. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation (2010)
    Geoffrey R. Oxnard, Maria E. Arcila et al. Clinical Cancer Research
  19. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay (2011)
    Maria E. Arcila, Geoffrey R. Oxnard et al. Clinical Cancer Research
  20. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease (2013)
    Kadoaki Ohashi, Yosef E. Maruvka et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 35 from Science/Nature 194 standout
Sub-graph 1 of 15

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
9 intermediate papers

Works of William Pao being referenced

Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers
2015
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
2011
and 11 more

Author Peers

Author Last Decade Papers Cites
William Pao 23852 20819 13960 231 35.0k
Gregory J. Riely 23302 19166 10730 358 30.7k
Lecia V. Sequist 17898 19112 10020 364 30.1k
Jeffrey A. Engelman 13540 15823 20979 181 35.4k
Tetsuya Mitsudomi 22217 17840 14384 530 35.9k
Vincent A. Miller 30167 29326 15829 476 44.8k
Rafael Rosell 16187 14871 9816 541 26.1k
Myung‐Ju Ahn 21982 21786 7271 708 31.1k
Federico Cappuzzo 16525 16586 6863 354 24.0k
Alice T. Shaw 18004 15554 9442 328 24.4k
Yasushi Yatabe 14927 14366 11845 632 31.1k

All Works

Loading papers...

Rankless by CCL
2026